Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 20/20 | 0.64 |
| ▸ | DRD3 | P35462 | 20/20 | 0.64 |
| ▸ | HTR1D | P28221 | 2/20 | 0.53 |
| ▸ | HTR1B | P28222 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5430736 | 1.00 | DRD2 (0.64) | DRD2DRD3HTR1DHTR1B | |
| SCHEMBL5421554 | 0.89 | DRD2 (0.76) | DRD2DRD3HTR1DHTR1B | |
| SCHEMBL5421547 | 0.89 | DRD2 (0.76) | DRD2DRD3HTR1DHTR1B | |
| SCHEMBL5425188 | 0.86 | DRD2 (0.59) | DRD2DRD3 | |
| SCHEMBL5425182 | 0.86 | DRD2 (0.59) | DRD2DRD3 | |
| SCHEMBL5425178 | 0.85 | DRD2 (0.61) | DRD2DRD3HTR1DHTR1B | |
| SCHEMBL5425166 | 0.84 | DRD2 (0.75) | DRD2DRD3HTR1DHTR1B | |
| SCHEMBL5425173 | 0.84 | DRD2 (0.75) | DRD2DRD3HTR1DHTR1B | |
| SCHEMBL5432117 | 0.83 | DRD2 (0.68) | DRD2DRD3HTR1DHTR1B | |
| SCHEMBL5432122 | 0.83 | DRD2 (0.68) | DRD2DRD3HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185090-A1 | Muscarinic acetylchoine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | claimed |
| US-20070185090-A1 | Muscarinic acetylchoine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185090-A1 | Muscarinic acetylchoine receptor antagonists | CHRM3, CHRNG, CHRM2 | DRD2 969/4885DRD3 1530/4885HTR1D 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.